|
1
|
Jiao K, Niu LN, Wang MQ, et al:
Subchondral bone loss following orthodontically induced cartilage
degradation in the mandibular condyles of rats. Bone. 48:362–371.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prasadam I, van Gennip S, Friis T, Shi W,
Crawford R and Xiao Y: ERK-1/2 and p38 in the regulation of
hypertrophic changes of normal articular cartilage chondrocytes
induced by osteoarthritic subchondral osteoblasts. Arthritis Rheum.
62:1349–1360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wenham CY and Conaghan PG: New horizons in
osteoarthritis. Age Ageing. 42:272–278. 2013. View Article : Google Scholar
|
|
4
|
Shimizu M, Tsuji H, Matsui H, Katoh Y and
Sano A: Morphometric analysis of subchondral bone of the tibial
condyle in osteoarthrosis. Clin Orthop Relat Res. 229–239.
1993.PubMed/NCBI
|
|
5
|
Bailey AJ, Mansell JP, Sims TJ and Banse
X: Biochemical and mechanical properties of subchondral bone in
osteoarthritis. Biorheology. 41:349–358. 2004.PubMed/NCBI
|
|
6
|
Kearns AE, Khosla S and Kostenuik PJ:
Receptor activator of nuclear factor kappaB ligand and
osteoprotegerin regulation of bone remodeling in health and
disease. Endocr Rev. 29:155–192. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Silva I and Branco JC: Rank/Rankl/opg:
literature review. Acta Reumatol Port. 36:209–218. 2011.PubMed/NCBI
|
|
8
|
Komuro H, Olee T, Kuhn K, et al: The
osteoprotegerin/receptor activator of nuclear factor
kappaB/receptor activator of nuclear factor kappaB ligand system in
cartilage. Arthritis Rheum. 44:2768–2776. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Upton AR, Holding CA, Dharmapatni AA and
Haynes DR: The expression of RANKL and OPG in the various grades of
osteoarthritic cartilage. Rheumatol Int. 32:535–540. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kwan Tat S, Pelletier JP, Lajeunesse D,
Fahmi H, Lavigne M and Martel-Pelletier J: The differential
expression of osteoprotegerin (OPG) and receptor activator of
nuclear factor kappaB ligand (RANKL) in human osteoarthritic
subchondral bone osteoblasts is an indicator of the metabolic state
of these disease cells. Clin Exp Rheumatol. 26:295–304. 2008.
|
|
11
|
Kwan Tat S, Amiable N, Pelletier JP, et
al: Modulation of OPG, RANK and RANKL by human chondrocytes and
their implication during osteoarthritis. Rheumatology (Oxford).
48:1482–1490. 2009.PubMed/NCBI
|
|
12
|
Feng ZY, He ZN, Zhang B and Chen Z:
Osteoprotegerin promotes the proliferation of chondrocytes and
affects the expression of ADAMTS-5 and TIMP-4 through MEK/ERK
signaling. Mol Med Rep. 8:1669–1679. 2013.PubMed/NCBI
|
|
13
|
Sagar DR, Ashraf S, Xu L, et al:
Osteoprotegerin reduces the development of pain behaviour and joint
pathology in a model of osteoarthritis. Ann Rheum Dis.
73:1558–1565. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim N, Odgren PR, Kim DK, Marks SC Jr and
Choi Y: Diverse roles of the tumor necrosis factor family member
TRANCE in skeletal physiology revealed by TRANCE deficiency and
partial rescue by a lymphocyte-expressed TRANCE transgene. Proc
Natl Acad Sci USA. 97:10905–10910. 2000. View Article : Google Scholar
|
|
15
|
Watanabe Y, Namba A, Aida Y, et al:
IL-1beta suppresses the formation of osteoclasts by increasing OPG
production via an autocrine mechanism involving celecoxib-related
prostaglandins in chondrocytes. Mediators Inflamm. 2009:3085962009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mandelin J, Li TF, Hukkanen M, et al:
Interface tissue fibroblasts from loose total hip replacement
prosthesis produce receptor activator of nuclear factor-kappaB
ligand, osteoprotegerin, and cathepsin K. J Rheumatol. 32:713–720.
2005.
|
|
17
|
Palmqvist P, Persson E, Conaway HH and
Lerner UH: IL-6, leukemia inhibitory factor, and oncostatin M
stimulate bone resorption and regulate the expression of receptor
activator of NF-kappa B ligand, osteoprotegerin, and receptor
activator of NF-kappa B in mouse calvariae. J Immunol.
169:3353–3362. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kusumi A, Sakaki H, Kusumi T, et al:
Regulation of synthesis of osteoprotegerin and soluble receptor
activator of nuclear factor-kappaB ligand in normal human
osteoblasts via the p38 mitogen-activated protein kinase pathway by
the application of cyclic tensile strain. J Bone Miner Metab.
23:373–381. 2005. View Article : Google Scholar
|
|
19
|
Wang YD, Tao MF, Wang L, Cheng WW and Wan
XP: Selective regulation of osteoblastic OPG and RANKL by
dehydroepiandrosterone through activation of the estrogen receptor
β-mediated MAPK signaling pathway. Horm Metab Res. 44:494–500.
2012.PubMed/NCBI
|
|
20
|
Moreno-Rubio J, Herrero-Beaumont G, Tardio
L, Alvarez-Soria MA and Largo R: Nonsteroidal antiinflammatory
drugs and prostaglandin E(2) modulate the synthesis of
osteoprotegerin and RANKL in the cartilage of patients with severe
knee osteoarthritis. Arthritis Rheum. 62:478–488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ying X, Chen X, Cheng S, Shen Y, Peng L
and Xu HZ: Piperine inhibits IL-β induced expression of
inflammatory mediators in human osteoarthritis chondrocyte. Int
Immunopharmacol. 17:293–299. 2013.
|
|
22
|
Zeng L, Wang W, Rong XF, et al:
Chondroprotective effects and multi-target mechanisms of Icariin in
IL-1 beta-induced human SW 1353 chondrosarcoma cells and a rat
osteoarthritis model. Int Immunopharmacol. 18:175–181. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schluesener JK and Schluesener H: Plant
polyphenols in the treatment of age-associated diseases: revealing
the pleiotropic effects of icariin by network analysis. Mol Nutr
Food Res. 58:49–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma HR, Wang J, Chen YF, Chen H, Wang WS
and Aisa HA: Icariin and icaritin stimulate the proliferation of
SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK
signaling pathway. Int J Mol Med. 33:1627–1634. 2014.PubMed/NCBI
|
|
25
|
Zhang X, Liu T, Huang Y, Wismeijer D and
Liu Y: Icariin: does it have an osteoinductive potential for bone
tissue engineering? Phytother Res. 28:498–509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu MH, Sun JS, Tsai SW, Sheu SY and Chen
MH: Icariin protects murine chondrocytes from
lipopolysaccharide-induced inflammatory responses and extracellular
matrix degradation. Nutr Res. 30:57–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Zhang X, Li KF, et al: Icariin
promotes extracellular matrix synthesis and gene expression of
chondrocytes in vitro. Phytother Res. 26:1385–1392. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li GW, Xu Z, Chang SX, Nian H, Wang XY and
Qin LD: Icariin prevents ovariectomy-induced bone loss and lowers
marrow adipogenesis. Menopause. 21:1007–1016. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pei Z, Zhang F, Niu Z and Shi S: Effect of
icariin on cell proliferation and the expression of bone
resorption/formation-related markers in human periodontal ligament
cells. Mol Med Rep. 8:1499–1504. 2013.PubMed/NCBI
|
|
30
|
Wang JJ, Huan SK, Hsieh KH, et al:
Inhibitory effect of midazolam on MMP-9, MMP-1 and MMP-13
expression in PMA-stimulated human chondrocytes via recovery of
NF-κB signaling. Arch Med Sci. 9:332–339. 2013.PubMed/NCBI
|
|
31
|
Choi YS, Park JK, Kang EH, et al: Cytokine
signaling-1 suppressor is inducible by IL-1beta and inhibits the
catabolic effects of IL-1beta in chondrocytes: its implication in
the paradoxical joint-protective role of IL-1beta. Arthritis Res
Ther. 15:R1912013. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Furumatsu T, Matsumoto E, Kanazawa T, et
al: Tensile strain increases expression of CCN2 and COL2A1 by
activating TGF-β-Smad2/3 pathway in chondrocytic cells. J Biomech.
46:1508–1515. 2013.PubMed/NCBI
|
|
33
|
Jia P, Chen G, Zhou G, Zhong Y and Li R:
Fuyuan Decoction inhibits nitric oxide production via inactivation
of nuclear factor-κB in SW1353 chondrosarcoma cells. J
Ethnopharmacol. 146:853–858. 2013.PubMed/NCBI
|
|
34
|
van der Kraan PM: Understanding
developmental mechanisms in the context of osteoarthritis. Curr
Rheumatol Rep. 15:3332013.PubMed/NCBI
|
|
35
|
Naumov AV: Current possibilities of
correcting subchondral bone resorption as a major pathogenetic
factor for progressive osteoarthrosis. Ter Arkh. 86:60–65. 2014.(In
Russian).
|
|
36
|
Saller R and Rostock M: Multimorbidity and
multi-target-therapy with herbal drugs. Praxis (Bern 1994).
101:1637–1642. 2012.(In German).
|
|
37
|
Zheng CS, Xu XJ, Ye HZ, et al: Network
pharmacology-based prediction of the multi-target capabilities of
the compounds in Taohong Siwu decoction, and their application in
osteoarthritis. Exp Ther Med. 6:125–132. 2013.PubMed/NCBI
|
|
38
|
Zhang W, Li R, Wang S, Zhou X and Zhong Y:
Study of molecular mechanisms of fuyuan capsule, icariin and
arasaponin R1 in treatment of osteoarthritis. Zhongguo Zhong Yao Za
Zhi. 36:2113–2117. 2011.(In Chinese).
|
|
39
|
Yang L, Yu Z, Qu H and Li M: Comparative
effects of hispidulin, genistein, and icariin with estrogen on bone
tissue in ovariectomized rats. Cell Biochem Biophys. 70:485–490.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mok SK, Chen WF, Lai WP, et al: Icariin
protects against bone loss induced by oestrogen deficiency and
activates oestrogen receptor-dependent osteoblastic functions in
UMR 106 cells. Br J Pharmacol. 159:939–949. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Daheshia M and Yao JQ: The interleukin
1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol.
35:2306–2312. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Roman-Blas JA, Contreras-Blasco MA, Largo
R, Alvarez-Soria MA, Castaneda S and Herrero-Beaumont G:
Differential effects of the antioxidant n-acetylcysteine on the
production of catabolic mediators in IL-1beta-stimulated human
osteoarthritic synoviocytes and chondrocytes. Eur J Pharmacol.
623:125–131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Haynes DR, Barg E, Crotti TN, et al:
Osteoprotegerin expression in synovial tissue from patients with
rheumatoid arthritis, spondyloarthropathies and osteoarthritis and
normal controls. Rheumatology (Oxford). 42:123–134. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ramos YF, Bos SD, van der Breggen R, et
al: A gain of function mutation in TNFRSF11B encoding
osteoprotegerin causes osteoarthritis with chondrocalcinosis. Ann
Rheum Dis. Apr 17–2014.(Epub ahead of print).
|
|
45
|
Usui M, Xing L, Drissi H, et al: Murine
and chicken chondrocytes regulate osteoclastogenesis by producing
RANKL in response to BMP2. J Bone Miner Res. 23:314–325. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kusumi A, Kusumi T, Miura J and Tateishi
T: Passage-affected competitive regulation of osteoprotegerin
synthesis and the receptor activator of nuclear factor-kappaB
ligand mRNA expression in normal human osteoblasts stimulated by
the application of cyclic tensile strain. J Bone Miner Metab.
27:653–662. 2009. View Article : Google Scholar
|
